Epithelial growth factor receptor interacting agents (Q35038746)

5 August 2017

1 reference

title

Epithelial growth factor receptor interacting agents (English)

1 reference

5 August 2017

1

Jose Baselga

1 reference

5 August 2017

2

Joan Albanell

1 reference

5 August 2017

1 October 2002

1 reference

Hematology / Oncology Clinics of North America

5 August 2017

1 reference

5 August 2017

16

1 reference

5 August 2017

5

1 reference

5 August 2017

1041-1063

1 reference

Growth factors and cancer

5 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900055-2

7 January 2021

The ErbB signaling network: receptor heterodimerization in development and cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900055-2

7 January 2021

Regulation of signal transduction and signal diversity by receptor oligomerization

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900055-2

7 January 2021

Signal transduction through MAP kinase cascades

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900055-2

7 January 2021

AKT/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositide-dependent phosphorylation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900055-2

7 January 2021

New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900055-2

7 January 2021

The EGF receptor provides an essential survival signal for SOS-dependent skin tumor development

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900055-2

7 January 2021

Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900055-2

7 January 2021

Expression in rat fibroblasts of a human transforming growth factor-alpha cDNA results in transformation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900055-2

7 January 2021

Epidermal growth factor-related peptides and their receptors in human malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900055-2

7 January 2021

Presence of epidermal growth factor receptor as an indicator of poor prognosis in patients with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900055-2

7 January 2021

Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900055-2

7 January 2021

The ErbB receptors as targets for breast cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900055-2

7 January 2021

ZD1839 ('Iressa') as an anticancer agent

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900055-2

7 January 2021

Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900055-2

7 January 2021

Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900055-2

7 January 2021

Blockade of the epidermal growth factor receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu + MMTV/TGF-alpha bigenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900055-2

7 January 2021

Reversible G(1) arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires up-regulation of p27(KIP1) independent of MAPK activity

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900055-2

7 January 2021

Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900055-2

7 January 2021

Receptor blockade with monoclonal antibodies as anti-cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900055-2

7 January 2021

Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900055-2

7 January 2021

Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900055-2

7 January 2021

Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900055-2

7 January 2021

Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900055-2

7 January 2021

Induction of apoptosis in fibroblasts by c-myc protein

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900055-2

7 January 2021

Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900055-2

7 January 2021

Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900055-2

7 January 2021

Tumor epidermal growth factor receptor studies in patients with non-small-cell lung cancer or head and neck cancer treated with monoclonal antibody RG 83852

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900055-2

7 January 2021

Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900055-2

7 January 2021

Multiple infusions of anti-epidermal growth factor receptor (EGFR) monoclonal antibody (EMD 55,900) in patients with recurrent malignant gliomas.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900055-2

7 January 2021

Requirement for intrinsic protein tyrosine kinase in the immediate and late actions of the EGF receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900055-2

7 January 2021

A specific inhibitor of the epidermal growth factor receptor tyrosine kinase

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900055-2

7 January 2021

Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900055-2

7 January 2021

CI-1033, a pan-erbB tyrosine kinase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900055-2

7 January 2021

Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900055-2

7 January 2021

Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900055-2

7 January 2021

The pursuit of optimal outcomes in cancer therapy in a new age of rationally designed target-based anticancer agents

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2802%2900055-2

7 January 2021

10.1016/S0889-8588(02)00055-2

Identifiers

DOI

1 reference

5 August 2017

1 reference

PubMed ID

12512382